The bioanalytical testing services market is experiencing a significant upswing, driven by the escalating global drug development activities. As pharmaceutical and biotechnology companies intensify their efforts to bring new therapies to market, the demand for bioanalytical testing services, crucial for drug safety and efficacy assessments, is on the rise.
The view of the market is literally witnessing a noteworthy trend towards biologics and biosimilars. Since the number of biopharmaceutical product in development is rising rapidly, hence bioanalytical testing services are regarded important for ensuring the quality, safety and efficacy of these complex therapeutic molecules which all add to stable growth trend.
Biomarker testing is moving upwards with biotechnology bioanalytical services. Instead for focusing on tumor mass, the drug development industry begins to focus more on personalized medicine by developing treatments that target and manipulate patient’s own healthy cells, which is only possible with biomarker testing because without proper personalization treatment of diseases such as Alzheimer’s might prove fatal. This also creates a demand for specialized bioanalytical services.
The demand for comprehensive drug testing solutions emerged due to the increasing popularity of contract research organizations (CROs). CROs give the first option platform where drug development companies can get bioanalytical services that lessen paper work in drug development to ensure efficiency and affordable services.
Bioanalytical testing continues to raise a concern on real-world evidence, whose importance is increasing. Beyond the limited scope of traditional clinical trial data, real-world evidence integration in drug development would need to incorporate specialized testing services aimed at evaluating not only the efficacy and safety of drugs among patients that are typically different from those seen during clinical trials but also their outcomes under frequently changing routine practice patterns.
Nowadays, a need for quick-diagnosis and point-of-care testing services is becoming more and more apparent. In the growing demand for speedier decision-making processes in drug creation, quick bioanalytical testing services turn out to be more precious in niche markets; a service that is feasible on location also generates high market growth. The globalization of clinical trials is influencing the bioanalytical testing services market. With clinical trials conducted in diverse geographical locations, there is a need for standardized and harmonized bioanalytical testing services to ensure consistent and reliable data across different regions.
Bioanalytical Testing Services Market Size was valued at USD 3.57 Billion in 2023. The Global Bioanalytical Testing Services industry is projected to grow from USD 3.90 Billion in 2024 to USD 8.10 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.54% during the forecast period (2024 - 2032).
The bioanalytical testing services play a vital role in the quantification of drugs and drug manufacturing, they help in determining the purpose of the drug and whether or not it meets the requirements for which it is discovered. Therefore, the growth of the bioanalytical testing services is reliant on the growth of the medical industry, which has been growing at a faster pace in recent times. The validation of the pharmaceutical drugs that validate the accuracy, precision, selectivity, stability, and other parameters are carried out in the bioanalytical testing process.
The increasing number of chronic illnesses, cancer, and other ailments has increased the demand for efficient medical treatments and these biopharmaceutical companies are relying on the results obtained through bioanalytical testing services. Moreover, there are several stages a drug has to undergo to prove its efficacy and safety, such drug development stages are carried out by the industry. Such responsible roles of the industry owners and the significance of the industry are considered the primary drivers of bioanalytical testing services market growth.
The largest independent laboratory in the US for kidney dialysis testing, Ascend Clinical, LLC, will be acquired by Eurofins Scientific, a leader in bioanalytical testing, in 2024. Ascend, which was established in 2000, employs 170 people and runs a cutting-edge laboratory in Sunnyvale, California. The company offers dialysis clinics and hospitals around the country highly automated chemistry, hematology, microbiology, and virology testing services.
the 2022 North American Customer Value Leadership Award to Inotiv, Inc. in 2023. Inotiv operates in the contract research services and research product business segments to cater to the demands of drug and device makers involved in bio-analytical, non-clinical, and clinical research. It provides a variety of skilled scientists and cutting edge facilities to deliver highly competitive and thorough. The company's broad portfolio, excellent bio-analytical skills, and strategic acquisitions make it stand out.
We are happy to announce the growth of our leadership team for 2023 at KCAS Bioanalytical and Biomarker Services, in conjunction with our recently acquired FlowMetric and Active Biomarkers. The business is extending the reach of KCAS's bioanalytical and biomarkers domains.
COVID 19 Analysis:
The widespread of COVID 19 has affected the productivity of the industrial sectors and as the widespread has affected several global operations, the demand for effective vaccines, treatments, and other medical services was rising. Therefore the bioanalytical testing services market demand was also surging during the pandemic. The medical centers were reliant on the point of care services, and screening methods for early detection of viruses in people. Such factors have augmented the growth of the bioanalytical testing services industry. Moreover, the companies have brought in innovative techniques and technologies that have eliminated the time consumption for the processing. The key techniques such as mass spectrometry, ultra-performance liquid chromatography, automated sample preparation, and significant others. such advanced technologies that adopted robotics and barcode systems have proved efficient during the pandemic.
Market drivers:
The increasing drug development and the increasing investment in biotechnology companies and their adoption of advanced technologies are considered the major drivers of the bioanalytical testing services industry. Moreover, the increasing number of cancer patients across the globe and the tests conducted related to oncology are considered the key drivers of bioanalytical testing services market growth.
The significance of the bioanalytical testing services such as its primary role in drug discovery, drug development, innovative drug development, and testing are some of the major drivers of the bioanalytical testing services industry. Moreover, these contract research organizations are funded by government organizations and the growing biosimilar development are some of the factors that fuel the overall growth of the bioanalytical testing services industry.
Market Opportunities:
The advent of advanced and versatile platforms that improves innovative methods has impacted the growth of bioanalytical testing services. The modern techniques in the industry are well equipped to face the challenges that might appear and therefore the field of bioanalysis is matured in recent times. Such factors are expected to increase the overall growth of the bioanalytical testing services industry.
The leading market players like SGS are adopting advanced technologies such as Dry blood spot technology during the quantification of pharmacokinetics that offers more advantages than other conventional methods. some of the key benefits of the dry blood spot method are they require a minimal sample for processing, they offer convenient sample storage, exhibit low biohazard risks, don’t require post-collection processing and significant others. Therefore the presence of advanced technologies is simplifying the quantification process and thereby expected to increase the bioanalytical testing services market during the forecast period.
Market restraints:
The complicated regulatory requirements and the complications with the software are considered the major restraints of the bioanalytical testing services market.
The evolution of the instruments while complying with the regulations and the issues that might arise during the validation of these instruments are considered the major challenge for the overall growth of the bioanalytical testing service industry.
Market challenges:
Higher capital investment is required for the discovery of the medicines and to perform clinical stages. This is considered the major challenge for the overall growth of the bioanalytical testing services industry.
Lack of expertise in the industry with regular standards is considered the major challenge for the bioanalytical testing services market growth. On the other hand, the developed countries are mandating the vendors and manufacturers to comply with the regulations imposed on the industry. These regulations enhance the quality and consistency of the data and thereby support the approval of chemical or biological drugs. Minute changes from the standards are acceptable; however, scientific justifications are expected. Such factors are considered the key challenge for the bioanalytical testing services market growth.
Cumulative growth analysis:
The growth of the bioanalytical testing services industry is due to the favorable economic efficiency of the key market layers. Moreover, the pharmaceutical companies are improving their R and D activities and core competencies which are stimulating the overall growth of the bioanalytical testing services industry.
The growing competitive pressure and concerns related to pricing are propelling the companies to develop the existing bioanalytical testing technologies. Such factors are presenting lucrative opportunities for the bioanalytical testing services market growth during the forecast period. The demand for specific testing procedures is increasing in the market, as the key developers are enhancing biosimilars, combination products, and innovative medicines.
Bioanalytical Testing Services Market Value chain analysis:
The growth of the bioanalytical testing services industry is expected to increase during the forecast period as several diverse drug manufacturers are working to develop reliable analytical methods with accuracy and robustness. Moreover, the contract manufacturers are also observing higher demand for sophisticated analytical testing services and therefore propelling the overall growth of the bioanalytical testing services industry. Similarly, the large companies are replenishing their pipelines, which is investing in their R and D, and therefore the complexity of these services is increasing and the organizations are complying with the standards and regulations imposed on them. Such factors are considered the major drivers of bioanalytical testing services market growth.
Especially the growth across the serology, immunogenicity, and antibodies are showcasing higher market value as the demand for the drugs and the development of drugs across these segments are higher. Similarly, the demand for the molecule bioanalytical testing services is higher as there are higher investments made in the development of biological drugs and amino acid-based molecules. The providers of the tools are providing the necessary tools required for technological expertise.
Bioanalytical Testing Services Market Regional analysis:
Currently, North America is leading in the bioanalytical testing services market value and is expected to hold the position during the forecast period, which is due to the facilities available across the region and increasing investment for the R and D from US pharmaceutical titans. They are also intensively focusing to develop new drugs and have already produced over 1100 oncology drugs which are currently at various stages of clinical development. The presence of leading market players such as Pfizer is propelling the overall growth of the bioanalytical testing services industry across North America.
On the other hand, the Asia-pacific region is also expected to grow at a steady rate during the forecast period, due to the presence of several pharmaceutical companies and an increasing number of CROs across the region, they are working towards the drug discovery and development services at affordable price.
Bioanalytical Testing Services Market Competitive landscape:
Recent developments:
In the year 2019, one of the leading market players, Adial pharmaceuticals joined hands with Eurofins Scientific company to expand its service area and improve its portfolio. Specifically, they have developed a therapeutic agent that treats alcohol use disorder.
In the year 2021, one of the established market players, the Eurofins bioanalytical services division launched a surrogate virus neutralization antibody that is to treat COVID 19, later which got the approval from FDA.
Bioanalytical Testing Services Market Report overview:
This report has covered:
Based on the test:
Based on type:
Based on workflow:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)